Vitamin D and green tea extract resulted in a significant reduction in the mean size of uterine fibroids among women of later reproductive age, according to a recent study.
The concomitant administration of vitamin D and green tea extract resulted in a significant reduction in the mean size of uterine fibroids among women of later reproductive age, according to a pilot study in the journal Gynecological Endocrinology.1
The positive effect of the combined treatment was also more pronounced in women with predominant intramural (IM) fibroids than those with subserosal (SS) fibroids greater than or equal to 3 cm.
“Fibroids are a common gynecological disease, with a cumulative incidence of approximately 70% in White women and 80% in Black women by age 50,” said principal investigator Giovanni Grandi, MD, an assistant professor of ob-gyn at the University of Modena and Reggio Emilia in Modena, Italy
The beneficial effects of vitamin D and epigallocatechin gallate (EGCG), a polyphenol of green tea, on the growth of uterine fibroids were previously described in vitro and in vivo, according to Grandi, “and recent studies indicate that hypovitaminosis D plays a role in fibroid development,” he said. “Moreover EGCG has some chemopreventive and anticancer potentials that have demonstrated an antiproliferative effect on fibroid cells.”
The current prospective study, which was conducted at the Azienda Ospedaliero-Universitaria Policlinico of Modena from January 2020 to February 2021, recruited 16 premenopausal women, all over the age of 40.
The women either had IM fibroids or SS fibroids ≥3 cm, or several fibroids of various sizes with a total diameter between ≥3 cm and <10 cm.
In addition, none of the women had further accompanying organic causes of abnormal uterine bleeding or were using other concomitant hormonal treatments.
Participants were treated with EGCG 300 mg, vitamin B6 10 mg, and vitamin D 50 µg/day for 90 days, for which they completed a daily diary on bleeding and pelvic pain.
At the end of the 90 days, there was a significant reduction in the mean size of the fibroids, with a 17.8% overall mean decrease (P = 0.03) and a 37.3% mean decrease in individual fibroids (P = 0.015).
This effect was more evident in women with predominant IM fibroids (P = 0.016) in comparison to SS fibroids.
However, no significant changes were observed for uterine and ovarian volume and endometrial thickness during treatment.
On the other hand, there was a significant reduction in menstrual flow length of 0.9 days (P = 0.04), with no modification in cycle length, menstrual flow intensity, and menstrual pain intensity.
“It was truly surprising to demonstrate after 3 months of treatment in women during late reproductive life, a clear reduction of about one third the volume of fibroids,” Grandi told Contemporary OB/GYN®. “It was also unexpected that women with predominant intramural fibers benefited more from treatment than those with SS fibroids.”
Grandi noted that patient satisfaction with treatment was largely very high, with no adverse effects reported.
“Today, only hormonal treatments are validated and available for fibroid management worldwide,” Grandi said. “The combination treatment of vitamin D and green tea extracts could be a new therapeutic nonhormonal option for women of late reproductive life for which hormonal manipulation is not foreseen.”
The same beneficial effect needs to be determined in larger randomized trials, especially in younger women under the age of 35 with uterine fibroids, according to Grandi.
Disclosure:
Grandi reports no relevant financial disclosures.
Reference:
1. Grandi G, Del Savio MC, Melotti C, et al. Vitamin D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study. Gynecol Endocrinol. Published online October 16, 2021. doi:10.1080/09513590.2021.1991909
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More